The National Institute of Health (NIH) is offering a free resource to the medical countermeasure research and development community via a new CounterACT Neurotherapeutics Screening (CNS) Program.
The purpose of the CNS program is to help provide applicants with important pre-application proof-of-concept efficacy data in support of a research proposals to the CounterACT or other federally-funded peer-reviewed grant program.
The overall goal of the effort is to accelerate the research and development of novel medical countermeasures for organophosphorus chemical threats that target the central nervous system.
The support is provided via a NIH-supported Department of Defense laboratory equipped to conduct translational research on the efficacy of compounds against the lethal and non-lethal effects of OP chemical threat agents in vivo. If accepted for the CNS program, studies are performed at no cost to the investigator/supplier.
The proposed studies must not overlap, but may be conducted in concert with, studies performed within other CounterACT efficacy, preclinical, grant programs. Participants will retain custody of and have primary rights to the data developed, subject to Government rights of access consistent with current U.S. Government policies.
The CNS program is available to U.S. investigators inside and outside of the CounterACT network with promising medical countermeasures for chemical threats. For more information, please contact Dave Yeung, Ph.D., Project Manager, CounterACT Program.
Read more: CounterACT Neurotherapeutics Screening (.pdf)
